Search

Your search keyword '"Furuse, Junji"' showing total 71 results

Search Constraints

Start Over You searched for: Author "Furuse, Junji" Remove constraint Author: "Furuse, Junji" Publisher elsevier bv Remove constraint Publisher: elsevier bv
71 results on '"Furuse, Junji"'

Search Results

1. Factors affecting nonfunctioning small pancreatic neuroendocrine neoplasms and proposed new treatment strategies

2. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

3. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

5. PS3-5 Futibatinib for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Japanese sub-analysis of FOENIX-CCA2

6. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto

7. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

8. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)

9. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

10. Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis

11. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial

14. A Randomized Phase II Study of Modified FOLFIRINOX Versus Gemcitabine Plus Nab-Paclitaxel for Locally Advanced Pancreatic Cancer (JCOG1407)

15. Safety and Efficacy of S-IROX (S-1, Irinotecan And Oxaliplatin Combination Therapy) in Patients with Advanced Pancreatic Cancer: A Multicenter Phase 1b Dose-Escalation and Dose-Expansion Clinical Trial

16. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

18. MO38-3 Clinical update with genomic analyses in expansion part of phase 1 study of selective FGFR inhibitor E7090

19. P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer

20. Risk stratification and prognostic factors in patients with unresectable undifferentiated carcinoma of the pancreas

21. Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial

22. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

23. Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups

24. Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study)

26. Long-Term Results of High-Dose 2-Fraction Carbon Ion Radiation Therapy for Hepatocellular Carcinoma

27. A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer (WJOG10417GTR)

28. Biomarkers and clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040

29. Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer

30. Phase I study of nivolumab or nivolumab/cisplatin/gemcitabine to treat unresectable/recurrent biliary tract cancer

31. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

32. 141 – Assessment of Preoperative Diagnostic Accuracy of Multidetector-Row Computed Tomography (MDCT) for Resectable Biliary Cancer: Multi-Institutional Validity Study in Japan

34. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)

35. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407)

36. A multicenter, open-label, uncontrolled study of ONO-7643/anamorelin in cachexia patients with gastrointestinal cancer

37. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

39. S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial

40. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study

41. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

42. Current status of FOLFIRINOX in Japan: modified or original?

43. Surgery for pancreatic neuroendocrine carcinoma (pNEC): A subgroup analysis of Japan pNEC study

46. Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC)

47. Rb expression and KRAS mutation as predictors of response to platinum-based chemotherapy (PBC) of small and large cell neuroendocrine carcinoma (NEC): A subgroup analysis of the Japan pNEC study

48. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

49. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer

Catalog

Books, media, physical & digital resources